SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare is trending sharply higher as it nears NASDAQ compliance, fueling strong community discussion and anticipation for potential positive FDA news regarding its sleep apnea drug, IHL-42X. Investors are actively debating the company's significant undervaluation relative to its cash position and pipeline, with many seeing substantial upside potential as compliance de-risks the stock and a major drug catalyst looms.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending following its development agreement with Tower Semiconductor, a move the community views as a major validation and acceleration toward scalable manufacturing integration of its electro-optic polymer technology. This deal is sparking widespread speculation of implied collaborations with NVIDIA and TSMC, driving excitement for its pivotal role in next-gen AI infrastructure and anticipation of a short squeeze.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health (HIMS) is surging after a major partnership with Novo Nordisk and the dismissal of a lawsuit removed a key overhang, sparking widespread community discussion around a potential short squeeze. Its notable resilience and high short interest are driving bullish sentiment, with many anticipating further upward momentum even amidst a down market.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is trending due to escalating geopolitical tensions and reports of attacks on oil tankers and infrastructure near the Strait of Hormuz, driving community debate on whether record oil reserve releases can effectively counter potential global supply disruptions.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending amidst renewed acquisition speculation, with French reports indicating interest from both Eli Lilly and AstraZeneca, leading the community to anticipate a significant buyout premium given AstraZeneca's European presence and obefazimod's promising data for ulcerative colitis.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending after delivering a strong earnings beat, achieving GAAP profitability for the first time, and announcing a new $500 million stock buyback, sparking intense community debate between bulls highlighting high short interest and AI agent opportunities, and skeptics citing modest growth guidance amid volatile post-earnings price action.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is a hot topic as investors question its stock performance despite strong fundamentals, including robust Autoship growth and expansion into vet care. The community is sharply divided between those pointing to significant institutional buying and analyst upgrades as signs of undervaluation, and others expressing frustration over recent leadership changes and the stock's continued struggle ahead of its anticipated March 25th earnings report.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is trending after naming Josh D'Amaro as the new CEO to succeed Bob Iger, a move that coincides with strong Q1 earnings, including record revenue from its Parks division and a new share buyback program. The community is actively debating if this leadership change, combined with improved streaming profitability, can finally drive a sustained turnaround for the media giant.

Almonty Industries, Inc. engages in mining, processing and shipment of tungsten concentrates. Its projects include Los Santos, Valtreixal, Almonty Korea Tungsten, Almonty Korea Moly, and Panasquiera. The company was founded on September 28, 2009 and is headquartered in Toronto, Canada.

Almonty Industries Inc

Almonty Industries is witnessing remarkable upward momentum, driven by surging tungsten prices and recent analyst upgrades, as the community celebrates its strategic position as a leading tungsten producer outside China and anticipates further growth amid increasing institutional interest in critical minerals.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending amidst market volatility driven by conflicting signals on U.S. government critical mineral support policies, even as the company's strategic importance in establishing a domestic rare earth supply chain for defense and advanced technologies remains a key community talking point.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Upstream Bio (NASDAQ:UPB) Trading 14.4% Higher - Should You Buy?

Upstream Bio (NASDAQ:UPB) Stock Price Up 14.4% - What's Next...

Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday

Upstream Bio (NASDAQ:UPB) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 11. (View Earnings Report at...

Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) have been given an average rating of "Moderate Buy" by the five analysts that are presently covering the firm, MarketBeat.com reports. One...

Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56%

Upstream Bio (NASDAQ:UPB) reported top-line results from its Phase II VALIANT trial evaluating verekitug in adults with severe asthma, highlighting statistically significant reductions in annualized...

Upstream Bio (NASDAQ:UPB) Sees Large Volume Increase - Here's Why

Upstream Bio (NASDAQ:UPB) Sees Unusually-High Trading Volume - Here's What Happened...

Upstream Bio (NASDAQ:UPB) Trading Down 10.3% - Time to Sell?

Upstream Bio (NASDAQ:UPB) Trading Down 10.3% - Here's Why...

Upstream Bio (NASDAQ:UPB) Shares Gap Down - Here's Why

Upstream Bio (NASDAQ:UPB) Shares Gap Down - Should You Sell...

Biotech Stocks To Add to Your Watchlist - February 11th

Moderna, Danaher, Vertex Pharmaceuticals, Medpace, and Upstream Bio are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies...

Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts

Upstream Bio shares rise after Phase 2 data show its asthma drug cut attacks by up to 56% and improved lung function. The company plans late-stage trials.read more...

<ul class="summary-bullets"><li>Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile.</li><li>Verekitug reduced asthma attacks by 56% with 100 mg, and 39% with 400 mg compared to placebo.</li><li>Upstream has begun planning Phase 3 studies.&nbsp;</li></ul>Shares of Upstream Bio Inc. (UPB) crashed more than 40% on Wednesday despite the company announcing positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.<h2 class="st-heading-2">Details Of The Test</h2>Verekitug, which targets the thymic stromal lymphopoietin (TSLP) receptor, reduced annual asthma attacks by 56% with 100 mg and 39% with 400 mg compared to placebo. Patients also showed improved lung function. Patients received Verekitug every 12 weeks for the 100 mg dose or every 24 weeks for the 400 mg dose.&nbsp;Verekitug was generally well tolerated in the 478-patient study, supporting its safety profile. More than 90% of eligible participants have enrolled in the VALOUR long-term extension trial to further assess the treatment’s durability.“We intend to rapidly advance verekitug into Phase 3 trials in severe asthma and CRSwNP. In parallel, we also continue to progress verekitug in our ongoing Phase 2 VENTURE trial in patients with COPD, where we have enrolled more than 60% of patients to date,” said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio.&nbsp;<h2 class="st-heading-2">Phase 3 Studies Update</h2>Upstream Bio structured the VALIANT trial with endpoints intended to support potential approval filings, and has begun planning Phase 3 studies in severe asthma and CRSwNP, with registrational trials expected after regulatory discussions.The results reportedly aligned exactly with Amgen’s (AMGN) Tezspire in effectiveness. The drug requires 210 milligrams every four weeks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment for <a href="https://stocktwits.com/symbol/UPB">UPB</a> on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user said the market reaction was ‘unwarranted’.<stembedurl>https://stocktwits.com/stjernerogvann/message/644653420</stembedurl>Another user saw a buying opportunity.<stembedurl>https://stocktwits.com/lordBrian/message/644666591</stembedurl>Year-to-date, the stock has declined more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did UPB Stock Plunge 40% Today?

The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.

Equity

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.70	--	--	N/A
Q3 '25	-$0.68	-$0.63	7.62%	BEAT
Q2 '25	-$0.74	-$0.74	--	EXPECTED
Q1 '25	-$0.50	--	--	N/A
Q4 '24	-$0.49	--	--	N/A

UPB
Upstream Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest UPB News

UPBUpstream Bio Inc.